--- title: "Weekly Recap | 3SBIO +2.06%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/296674068.md" description: "3SBIO (1530.HK) closed the week at HK$17.83, up 2.06% over four trading days. The stock opened at HK$17.59 on Monday, then drifted lower through Tuesday and Wednesday, hitting an intraweek low of HK$16.34 on 19 August before settling at HK$16.50. Thursday told a different story: the shares opened at HK$16.42, surged to an intraday high of HK$18.65, and finally closed at HK$17.83 — a single-day swing of nearly 15%. The weekly amplitude reached 13." datetime: "2026-08-22T06:49:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296674068.md) - [en](https://longbridge.com/en/news/296674068.md) - [zh-HK](https://longbridge.com/zh-HK/news/296674068.md) generator: "portal-rs" --- # Weekly Recap | 3SBIO +2.06%, most brokers rate it buy ## The Week 3SBIO (1530.HK) closed the week at HK$17.83, up 2.06% over four trading days. The stock opened at HK$17.59 on Monday, then drifted lower through Tuesday and Wednesday, hitting an intraweek low of HK$16.34 on 19 August before settling at HK$16.50. Thursday told a different story: the shares opened at HK$16.42, surged to an intraday high of HK$18.65, and finally closed at HK$17.83 — a single-day swing of nearly 15%. The weekly amplitude reached 13.93%, with average daily volume of roughly 42.9m shares, about 46% above the 60-day median, signalling a sharp pickup in turnover. ## Key Events The week revolved around the company’s 2026 interim results. After Thursday’s close, 3SBIO posted its first-half numbers for the six months ended 30 June 2026, with net profit climbing 26.5% year-on-year to RMB 1.44 billion and revenue rising 3.9% to RMB 4.53 billion. When trading resumed on Friday, the stock gained 2%, as the market digested what early headlines described as mixed earnings. Subsequent coverage framed the results around an innovation-driven strategy and sustainable growth. Earlier in the week, sector-level commentary noted that Hong Kong biotech names were facing an earnings reality check, but the company’s own release quickly became the dominant narrative. ## Analyst Ratings The latest consensus shows 11 analysts covering the stock: 8 rate it buy, 2 rate it overweight, and 1 rates it hold, with no sell or underweight ratings. The consensus recommendation stands at strong buy, and the consensus target price is HK$32.84, implying roughly 84.2% upside from the current share price. Individual target prices range from HK$23.80 to HK$43.73, reflecting some dispersion at the upper end. Within the biotechnology sector, 3SBIO ranks 7th out of 51 peers covered. ## The Week Ahead With the interim results now in the market, the focus shifts to how investors digest the details and to any follow-up feedback from the analyst community. The stock staged a sharp rebound on earnings day, recovering most of the week’s earlier losses; whether it can hold above the HK$17.83 level will depend on how the market weighs the modest revenue growth against the pipeline story. Investors may also watch for any updates on the commercialisation progress of key products or new partnership announcements. ## In Short 3SBIO delivered a classic earnings-week swing this period — an early dip followed by a sharp rally on the results, with volumes surging well above their recent norm. The profit beat provided a clear catalyst, but the soft revenue line introduces a tension that the market will need to resolve. The analyst community remains firmly constructive, with a strong-buy consensus and a target price that sits more than 80% above spot. The question going forward is whether the earnings momentum can translate into sustained re-rating, or whether the revenue trajectory becomes the next point of debate. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [01530.HK](https://longbridge.com/en/quote/01530.HK.md) ## Related News & Research - [CICC Cuts 3SBIO TP 18% to HKD30, Lowers Earnings Forecasts; 1H Results In Line](https://longbridge.com/en/news/296869996.md) - [CMBI Slightly Cuts 3SBIO TP to HKD34.78, Reiterates Buy Rating](https://longbridge.com/en/news/296850928.md) - [Bitcoin, Ethereum, XRP, Dogecoin Hold Ground on Low-Volatility Monday](https://longbridge.com/en/news/296821534.md) - [Lenzing shareholders approve EUR 300 million capital increase at extraordinary meeting](https://longbridge.com/en/news/296902548.md) - [Shanghai Bao Pharma says FDA clears IND for KJ015 anti-HER2 bispecific antibody injection](https://longbridge.com/en/news/296768130.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**